J&J Medical Connect
XARELTO®

(rivaroxaban)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

Use of XARELTO in Diabetic Patients

Last Updated: 11/04/2026

Summary

  • In ROCKET AF, 40% (n=5695) of patients had diabetes mellitus (DM).1
    • In a prespecified subgroup analysis of the ROCKET AF study in patients with DM, the relative efficacy and safety of XARELTO vs warfarin were similar in patients with and without DM.
  • A retrospective review of electronic medical records found that diabetic patients on XARELTO had a higher incidence of major bleeding compared with nondiabetics.2
  • A retrospective, administrative claims database analysis conducted in patients with nonvalvular atrial fibrillation (NVAF) and diabetes found that compared with warfarin, XARELTO was associated with nonsignificant 32% and 22% hazard reductions in stroke/systemic embolism (SSE) and ischemic stroke, respectively. No differences in major bleeding were observed between groups.3
  • A retrospective, observational study conducted on patients with NVAF and DM newly initiating apixaban, dabigatran, XARELTO, or warfarin found that non-vitamin K oral anticoagulants (NOACs) were associated with variable rates of SSE and major bleeding when compared to warfarin.4
  • In a retrospective cohort analysis conducted in patients with NVAF and comorbid type 2 DM (T2DM), XARELTO was associated with an ~10% relative reduction in vascular mortality and fewer bleeding-related hospitalizations vs warfarin.5
  • In a study utilizing electronic health records, XARELTO was associated with reduced incidence rates of kidney and limb complications, and death in patients with NVAF and T2DM vs warfarin.6
  • In a large population-based cohort study that evaluated the effectiveness and safety of XARELTO vs apixaban in patients with NVAF and T2DM, comparable efficacy was found between apixaban and XARELTO in the prevention of stroke (hazard ratio [HR], 0.99; 95% confidence interval [CI], 0.79-1.23). Apixaban was associated with a decreased risk of major bleeding compared with XARELTO (HR, 0.68; 95% CI, 0.59-0.78); however, no difference in the risk of major adverse limb events (MALEs) was observed between the 2 groups (HR, 0.75; 95% CI, 0.54-1.04).7
  • In a subanalysis of a retrospective study (RIVA-DM) that evaluated the impact of age (<80 vs ≥80 years) on the effectiveness and safety of XARELTO vs warfarin in patients with NVAF and T2DM, no significant interaction for XARELTO vs warfarin by age was observed for any outcome, including SSE (HR, 0.95; 95% CI, 0.87-1.04 vs HR, 1.05; 95% CI, 0.92-1.19) and hospitalization for major bleeding or clinically relevant nonmajor bleeding (CRNMB; HR, 0.9; 95% CI, 0.84‑0.96 vs HR, 1.06; 95% CI, 0.96-1.18).8
  • In COMPASS (N=27,895):
    • A total of 37.7% (n=10,341) of patients in COMPASS had DM at baseline.9,10
    • A total of 31.2% (n=8555) of patients in COMPASS were on at least 1 hypoglycemic agent at baseline.11
    • The efficacy and safety of XARELTO plus aspirin vs aspirin alone were consistent in patients with and without DM at baseline.9,12
  • In VOYAGER PAD, 40% (n=2629) of patients had DM at baseline.13
    • The efficacy and safety of XARELTO plus aspirin vs aspirin alone were consistent in patients with and without DM at baseline.14
  • A post hoc analysis of the COMMANDER-HF study compared the efficacy and safety of low-dose XARELTO in heart failure patients with sinus rhythm and coronary disease with diabetes vs without diabetes. The event rates per 100 person-years (PY) for the primary efficacy outcome (a composite of death, nonfatal myocardial infarction [MI], or nonfatal stroke) were 16.23 vs 11.81 for patients with vs without diabetes (adjusted HR, 1.34; 95% CI, 1.19-1.5). The event rates per 100 PY for the primary safety outcome (a plus composite of fatal bleeding and bleeding into a critical space with the potential for permanent disability) were 0.47 vs 0.38 for patients with vs without diabetes (adjusted HR, 1.06; 95% CI, 0.56-2.01).15
  • In EINSTEIN DVT/PE (N=8281)16:
    • A total of 10.2% (n=843) of patients in EINSTEIN DVT/PE had DM at baseline, of whom 415 (10%) were in the XARELTO group and 428 (10.4%) were in the enoxaparin/vitamin K antagonist (VKA) group.
    • The efficacy and safety data for this subgroup of patients are not available.
  • Arjunan et al (2026) conducted a real-world study in patients with peripheral artery disease (PAD) and T2DM who underwent lower limb revascularization. Patients received XARELTO 2.5 mg twice daily plus aspirin 75 mg. At 1 year, MALEs occurred in 62 (61.4%) patients, and major adverse cardiovascular events (MACEs) occurred in 34 (33.7%) patients.17
  • Salle et al (2026) conducted a prospective study using data from the XATOA registry in patients with DM and cardiovascular disease (CVD) who initiated dual pathway inhibition (DPI) with XARELTO 2.5 mg twice daily plus aspirin. The study included patients with coronary artery disease (CAD) and/or PAD. Patients with DM had a 59% higher risk of major adverse vascular events (MAVEs), comprising MACEs and MALEs, compared with patients without DM (P<0.001).18
  • Chen et al (2026) conducted a retrospective cohort study using the clinical database of Tri-Service General Hospital in northern Taiwan to compare the effectiveness and safety of XARELTO, apixaban, dabigatran, and edoxaban in patients with DM and atrial fibrillation (AF) who received NOAC therapy for >3 months. Among the 175 XARELTO-treated patients included after propensity score matching, 12 MACEs (HR, 0.65; 95% CI, 0.32-1.35; P=0.251), 15 major bleeding events (HR, 1.61; 95% CI, 0.72-3.6; P=0.242), and 14 deaths (HR, 1.06; 95% CI, 0.49-2.28; P=0.878) were reported compared with apixaban.19
  • Ruigómez et al (2024) conducted a study using healthcare databases from Germany, the Netherlands, Sweden, and the UK to evaluate the safety of XARELTO compared with VKAs in patients receiving treatment for and secondary prevention of venous thromboembolism (VTE). Among XARELTO users with diabetes, intracranial bleeding incidence rates per 100 PY were 0 in the UK, not available in the Netherlands, 0.33 (95% CI, 0.2-0.51) in Germany, and 0.88 (95% CI, 0.42-1.84) in Sweden. All-cause mortality rates per 100 PY were 6.08 (95% CI, 4.11-8.69), 2 (95% CI, 0-8.1), 5.12 (95% CI, 4.55-5.74), and 5.13 (95% CI, 3.78-6.97), respectively.20
  • Additional citations identified during a literature search are included in the REFERENCES section for your review.21-33

CLINICAL STUDIES

Nonvalvular Atrial Fibrillation

ROCKET AF Study

The ROCKET AF study was a phase 3, randomized, double-blind, double-dummy, active-controlled, parallel-group, multicenter, event-driven, noninferiority study designed to evaluate the efficacy and safety of XARELTO 20 mg once daily with the evening meal (15 mg once daily with the evening meal in patients with creatinine clearance 30 to <50 mL/min) to warfarin (international normalized ratio, 2 to 3) for the prevention of stroke and systemic embolism (SE) in patients with NVAF at moderate-to-high risk for stroke.34

Patients were included, but not limited to the following in this study34:

  • Documented paroxysmal, persistent, or permanent AF with moderate-to-high risk of stroke
  • History of prior stroke, transient ischemic attack (TIA), or SE, or had ≥2 of the following risk factors (CHADS2 ≥2): heart failure or left ventricular ejection fraction ≤35%; hypertension; age ≥75 years; DM

Bansilal et al (2015)1 conducted a prespecified subgroup analysis of the ROCKET AF study to compare the efficacy and safety of XARELTO and warfarin in patients with (n=5695; 40%) or without (n=8569, 60%) DM.

  • The diagnosis of DM was based either on prior documentation of DM or treatment with glucose-lowering medications.
  • The primary efficacy endpoint was the composite of stroke (ischemic or hemorrhagic) and SE. The primary safety endpoint was the composite of both major bleeding and CRNMB.
  • After dose adjustments for renal function, 84% and 16% of patients with DM were assigned to XARELTO 20 mg and XARELTO 15 mg, respectively, as compared with 76% and 24% of patients without DM.
  • See Table: Efficacy and Safety Endpoints in Diabetic and Nondiabetic Patients.
  • In patients with DM randomized to XARELTO or warfarin, primary efficacy outcome rates were similar to those in patients without DM (interaction P=0.53).
  • In patients with DM randomized to XARELTO or warfarin, primary safety outcome rates (composite of major and nonmajor clinically relevant bleeding) were similar to those in patients without DM.
  • Major bleeding rates in patients with DM randomized to XARELTO or warfarin were similar to those in patients without DM (interaction P=0.43; HR, 0.98; 95% CI, 0.79-1.21; P=0.84). Nonmajor clinically relevant bleeding rates in patients with DM randomized to XARELTO or warfarin were similar to those in patients without DM (interaction P=0.17).

Efficacy and Safety Endpoints in Diabetic and Nondiabetic Patients1

History of Diabetes
No History of Diabetes
P-Value for Interaction
XAR Events/
100 pt-yrs (Total Events)

Warfarin Events/
100 pt-yrs (Total Events)

XAR vs Warfarin
HR (95% CI)

XAR Events/
100 pt-yrs (Total Events)

Warfarin Events/
100 pt-yrs (Total Events)

XAR vs Warfarin
HR (95% CI)

Efficacy Outcomes
SSE
1.74 (95)
2.14 (114)
0.82
(0.63-1.08)

2.12 (174)
2.32 (192)
0.92
(0.75-1.13)

0.53
Safety Outcomes
Major or nonmajor clinically relevant bleeding
14.81 (582)
15.44 (596)
0.98 (0.88-1.1)
14.99 (893)
13.94 (853)
1.09 (0.99-1.2)
0.17
Major bleeding
3.79 (165)
3.9 (169)
1 (0.81-1.24)
3.47 (230)
3.17 (217)
1.12 (0.93-1.35)
0.43
Hemorrhagic stroke
0.23 (10)
0.46 (20)
0.51 (0.24-1.09)
0.28 (19)
0.43 (30)
0.65 (0.37-1.16)
0.61
Intracranial hemorrhage
0.5 (22)
0.82 (36)
0.62 (0.36-1.05)
0.49 (33)
0.69 (48)
0.72 (0.46-1.12)
0.67
Abbreviations: CI, confidence interval; HR, hazard ratio; pt-yrs, patient-years; SSE, stroke/systemic embolism; XAR, XARELTO.

Patel et al (2016)2 retrospectively reviewed approximately 10 million electronic medical records from the Department of Defense Healthcare System to evaluate major bleeding-related hospitalizations in 44,793 patients prescribed XARELTO between 1/1/2013 and 6/30/2015 for NVAF.

  • A total of 12,039 (26.9%) XARELTO patients concomitantly had DM. Diabetic patients were more likely to be male, younger, and have more comorbidities and higher CHA2DS2VASc scores relative to nondiabetics.
  • Higher major bleeding rates were observed in diabetic patients compared to nondiabetics (3.68 vs 2.51 per 100 PY), with gastrointestinal bleeding as the most common site. Major bleeding fatality rate occurred in 2.3% in diabetics vs 3.7% in nondiabetics.

Coleman et al (2018)3 conducted a retrospective, administrative claims database analysis to assess efficacy and safety of XARELTO vs warfarin in patients with NVAF and diabetes treated in routine practice.

  • Using US Truven MarketScan claims data from November 2011 to December 2016, oral anticoagulant-naïve patients with NVAF and diabetes (type 1 or 2) and ≥12 months of continuous insurance coverage prior to the qualifying oral anticoagulant dispensing (index date) were identified.
  • XARELTO users (20 mg or 15 mg once daily) were 1:1 propensity score-matched to warfarin users and were followed until an event, oral anticoagulant switch/discontinuation, insurance disenrollment, or end of follow-up.
    • The standard XARELTO dose was defined as 20 mg. The reduced XARELTO dose was defined as 15 mg.
  • Primary efficacy outcome: combination of SSE, including ischemic stroke, hemorrhagic stroke, or SE; primary safety outcome: MB.
  • Of the 8424 XARELTO users and 11,348 warfarin users with NVAF and diabetes that were initially identified, 5517 XARELTO users (20% received the reduced 15-mg once-daily dose) and 5517 warfarin users were matched. Median follow-up was 1.5 years and ~97% had T2DM.
  • All baseline covariates evaluated were well balanced after propensity score-matching.
  • XARELTO-treated patients experienced nonsignificant reductions in SSE (0.87 vs 1.35/100 PY, respectively; HR, 0.68; 95% CI, 0.44-1.05) and ischemic stroke (0.69 vs 0.93/100 PY, respectively; HR, 0.78; 95% CI, 0.48-1.3) compared with warfarin-treated patients. No differences in overall major bleeding were observed (2.7 vs 3/100 PY, respectively; HR, 0.96; 95% CI, 0.74-1.25).
  • Results were similar when the analysis was limited to standard-dose XARELTO. Reduced dose XARELTO was associated with a significantly decreased hazard of SSE and ischemic stroke, without an increase in risk of major bleeding.

Lip et al (2020)4 conducted a retrospective, observational study comparing newly initiated apixaban, dabigatran, XARELTO, or warfarin in diabetic NVAF patients. The study analyzed data from the diabetes subgroup of the ARISTOPHANES study, 4 United States (US) commercial claims databases, and Centers for Medicare and Medicaid Services data to compare SE and major bleeding among a large NVAF population with diabetes. Patients were selected for analysis between January 01, 2013, to September 30, 2015.

Study Design/Methods

  • A total of 154,324 patients were included in the study. Following propensity score matching, the patients were included in 6 matched cohorts, the XARELTO cohorts are referenced in Table: Matched Cohorts.

XARELTO Matched Cohorts4
XARELTO vs warfarin
NOAC vs XARELTO
44,412 XARELTO-warfarin
36,549 apixaban-XARELTO
13,115 dabigatran-XARELTO
Abbreviation: NOAC, non-vitamin K oral anticoagulant.
  • Primary outcomes included time to first SSE, including ischemic stroke, hemorrhagic stroke, and SE, and time to first major bleeding, which included gastrointestinal bleeding, intracranial hemorrhage, and bleeding at other key sites.
  • Baseline characteristics related to demographic and clinical characteristics were well balanced for the matched populations.

Results

Rates of SSE and major bleeding of XARELTO compared to warfarin are referenced in Table: XARELTO and Warfarin Comparisons.


XARELTO and Warfarin Comparisons4
Comparator
Reference
Hazard Ratio
P-Value
Incidence rate
(per 100 person-years)

(95% CI)
XARELTO vs Warfarin (ref)
SSE
1.9
2.3
0.79 (0.71-0.89)
<0.001
Major Bleeding
7.3
7.1
1.02 (0.94-1.10)
0.67
Note: Incidence and hazard ratios of XARELTO vs warfarin. Incidence rates were measured per 100 person-years for matched NOAC cohorts. Hazard ratios were measured along with 95% CIs.
Abbreviations:
CI, confidence interval; NOAC, non-vitamin K oral anticoagulant; ref, reference; SSE, stroke/systemic embolism.

  • Rates of SSE and major bleeding compared across the NOACs and XARELTO are referenced in Table: XARELTO and NOAC Comparisons.

XARELTO and NOAC Comparisons4
Comparator
Reference
Hazard Ratio
P-Value
Incidence rate
(per 100 person-years)

(95% CI)
Apixaban vs XARELTO (ref)
SSE
1.7
1.8
0.87 (0.75-1)a
0.45
Major Bleeding
4.8
7.4
0.59 (0.54-0.65)
<0.001
Dabigatran vs XARELTO (ref)
SSE
1.8
1.6
1.11 (0.85-1.46)
0.44
Major Bleeding
4.8
6.4
0.76 (0.66-0.86)
<0.001
Note: Incidence and hazard ratios of XARELTO vs NOACs. Incidence rates were measured per 100 person-years for matched NOAC cohorts. Hazard ratios were measured along with 95% CIs.
Abbreviations:
CI, confidence interval; NOAC, non-vitamin K oral anticoagulant; ref, reference; SSE, stroke/systemic embolism.
aUpper limit of 95% was rounded from 0.997 to 1.00.

  • When compared to warfarin, this study found that apixaban and XARELTO were associated with a lower rate of SSE, whereas apixaban and dabigatran were associated with a lower rate of major bleeding compared to warfarin.

Coleman et al (2021)5 conducted a retrospective cohort analysis using Optum® De-Identified electronic health record data from November 2010 to December 2019 to evaluate the effectiveness and safety of XARELTO vs warfarin in NVAF patients with T2DM.

  • Adult patients with NVAF and comorbid T2DM, who were oral anticoagulant-naïve, newly started on XARELTO or warfarin, and had ≥12 months of prior electronic health record activity, were included in the analysis. Pregnant patients, patients with alternative indications for oral anticoagulation, and those with valvular heart disease were excluded.
  • The co-primary outcomes included the incidence rates (%/year) of developing the composite of SSE or vascular death (effectiveness) and major or CRNMB resulting in hospitalization (safety). Individual components of the composite outcomes were also assessed.
  • A total of 32,078 XARELTO (31% initiated on 15-mg dose) and 83,971 warfarin users (time-in-therapeutic range=47±28%) were identified and included in the analysis.
  • XARELTO was associated with a reduced risk of SSE or vascular death vs warfarin (3.79 vs 4.19, respectively; HR, 0.91; 95% CI, 0.88-0.95), driven primarily by reductions in vascular death (2.81 vs 3.18, respectively; HR, 0.9; 95% CI, 0.86-0.95) and SE (0.13 vs 0.16, respectively; HR, 0.82; 95% CI, 0.66-1.02).
  • Hospitalization for any type of major or CRNMB was less frequent with XARELTO vs warfarin (2.17 vs 2.31, respectively; HR, 0.94; 95% CI, 0.89-0.99) due to decreased critical organ bleeding (including intracranial hemorrhage) (0.35 vs 0.54, respectively; HR, 0.63; 95% CI, 0.55-0.72).

Costa et al (2021)6 conducted a study utilizing Optum de-Identified electronic health record data (November 2010 to December 2019) to evaluate the incidence rate of kidney, limb, and/or ophthalmic complications in patients with NVAF and T2DM newly prescribed XARELTO or warfarin.

  • Patients ≥18 years old, diagnosed with both NVAF and T2DM, and had a new prescription for XARELTO or warfarin were included in the study. Patients were excluded if they had previously received XARELTO for an indication other than NVAF, had valvular heart disease, prior oral anticoagulant use, or pregnant. Additional exclusion criteria included estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m2, a history of dialysis or kidney transplant, previous limb revascularization or amputation or diabetic retinopathy.
  • The primary outcome evaluated incidence rate of developing a composite outcome of >40% decrease in eGFR from baseline, eGFR <15 mL/min/1.73 m2, new diagnosis for dialysis or renal transplant, limb revascularization or major amputation, diabetic retinopathy development or all-cause mortality.
  • Included in the study were 24,912 XARELTO patients and 58,270 warfarin patients.
  • XARELTO was associated with a reduced hazard of the composite outcome (HR, 0.93, 95% CI, 0.91-0.95; absolute risk reduction: 1.97 events per 1000 PY; number needed-to-treat: 51) vs warfarin.
  • Additionally, XARELTO vs warfarin showed a significant reduction in the relative hazard of >40% decrease in eGFR from baseline (HR, 0.96), need for dialysis or renal transplant (HR, 0.81), and limb revascularization or major amputation (HR, 0.85). All-cause mortality occurred in 10.3/1000 PY fewer XARELTO vs warfarin users (HR, 0.92, 95% CI, 0.89-0.95).

Chowdhury et al (2022)7 conducted a large population-based cohort study using the United Kingdom’s Clinical Practice Research Datalink (CPRD) to evaluate the effectiveness and safety of XARELTO vs apixaban in patients with NVAF and T2DM.

  • Adult patients with NVAF and T2DM who were newly initiated on XARELTO or apixaban between January 1, 2013, and March 31, 2020, were included in the study. Patients with a history of valvular surgery or rheumatic valvular disease and hyperthyroidism were excluded. Additionally, patients who were diagnosed with VTE or underwent hip or knee surgery ≤30 days prior to the cohort entry date (ie, the date of the first XARELTO or apixaban prescription following AF diagnosis) were excluded.
  • The primary effectiveness outcome was a composite of hospitalization with incident ischemic stroke (or stroke not otherwise specified), TIA, or SE. The secondary effectiveness outcome included MALEs, a composite of major limb amputation and surgical or endovascular revascularization.
  • The safety outcome was major bleeding, defined as any bleeding requiring hospitalization or resulting in death.
  • After propensity score weighting, the XARELTO and apixaban groups consisted of 11,695 and 11,561 patients, respectively.35
    • After weighting, all baseline characteristics were well balanced across both groups.
  • The median duration of follow-up for the XARELTO and apixaban groups ranged from 300 to 313 and 285 to 293 days, respectively.
  • Incidence rates of stroke, major bleeding, and major limb events in the XARELTO and apixaban groups are presented in Table: XARELTO and Apixaban Comparisons.

XARELTO and Apixaban Comparisons7
Exposure
No. of Events
PY
Incidence Ratea (95% CI)
Adjusted HRb (95% CI)
Stroke
XARELTO
209
11,356.82
18.4 (16.1-21.1)
1 (ref)
Apixaban
319
13,658.37
23.4 (20.9-26.1)
0.99 (0.79-1.23)
Major limb events
XARELTO
108
11,389.41
9.5 (7.9-11.5)
1 (ref)
Apixaban
128
13,765.61
9.3 (7.8-11.1)
0.75 (0.54-1.04)
Major bleeding
XARELTO
607
11,097.83
54.7 (50.5-59.2)
1 (ref)
Apixaban
590
13,538.84
43.6 (40.2-47.2)
0.68 (0.59-0.78)
Abbreviations: CI, confidence interval; HR, hazard ratio; PY, person-years; ref, reference.
aPer 1000 PY.
bAdjusted using standardized mortality ratio weighting

Coleman et al (2022)8 conducted a subanalysis of a retrospective study (RIVA-DM) that used data from the Optum® De-Identified electronic health record database from November 2010 to December 2019 to evaluate the impact of age (<80 vs ≥80 years) on the effectiveness and safety of XARELTO vs warfarin in patients with NVAF and T2DM.

  • Adult patients with NVAF and T2DM who were newly initiated on XARELTO and warfarin were stratified into 2 subgroups, <80 and ≥80 years.
  • The primary outcomes included the incidence rates of developing SSE (effectiveness outcome) and hospitalization due to major or CRNMB (safety outcome).
  • Secondary outcomes included the composite of SSE/vascular death, any major bleeding, and MALEs.
  • Overall, 32,078 XARELTO and 83,971 warfarin users were identified and included in the main analysis.
    • A total of 25,472 XARELTO and 58,636 warfarin users were <80 years old, and 6606 XARELTO and 25,335 warfarin users were ≥80 years old.
  • After propensity score-overlap weighting, the mean (±standard deviation [SD]) age in the <80 and ≥80 years subgroups were 67 (±9) and 83 (±2) years, respectively.
  • The mean (±SD) duration of follow-up for XARELTO and warfarin was 2.9 (±1.9) and 2.9 (±2) years, respectively.
  • Incidence rates of SSE, hospitalization for major or CRNMB are referenced in Table: XARELTO and Warfarin Comparisons in Patients Aged <80 vs ≥80 Years.
  • No significant interaction for XARELTO vs warfarin by age was observed for any of the secondary outcomes, including vascular death (HR, 0.9 vs 0.92), MALE (HR, 0.76 vs 0.8), major bleeding (HR, 0.82 vs 0.77), or ICH (HR, 0.75 vs 0.68).

XARELTO and Warfarin Comparisons in Patients Aged <80 vs ≥80 Years8
Outcome
Incidence Rate in Patients Aged
<80 Years (%/Year)

Incidence Rate in Patients Aged
≥80 Years (%/Year)

XARELTO
(n=25,472)

Warfarin
(n=58,636)

HR
(95% CI)

XARELTO
(n=6606)

Warfarin
(n=25,335)

HR
(95% CI)

Primary outcomes
SSE
1.15
1.21
0.95a
(0.87-1.04)

2.08
1.98
1.05
(0.92-1.19)

Hospitalization for major or CRNMB
2
2.22
0.9a
(0.84-0.96)

3.29
3.09
1.06
(0.96-1.18)

Abbreviations: CI, confidence interval; CRNMB, clinically relevant nonmajor bleeding; HR, hazard ratio; SSE, stroke/systemic embolism.
aPinteraction ≥0.23.

Coronary Artery Disease and Peripheral Artery Disease

COMPASS Study

COMPASS was a phase 3, event-driven, double-blind, randomized, controlled study that compared treatment with XARELTO (2.5 mg twice daily) plus aspirin (100 mg once daily) vs aspirin alone (100 mg once daily) or XARELTO alone (5 mg twice daily) vs aspirin alone (100 mg once daily) in patients with stable CAD or PAD.9

  • A total of 27,395 patients were enrolled in the study and 37.7% (n=10,341) of patients had DM.
  • At baseline, 8555 patients (31.2%) within the COMPASS study were on at least 1 hypoglycemic agent. Of those patients, 2840 had been in the XARELTO-plus-aspirin group, 2829 had been in the XARELTO-alone group, and 2886 had been in the aspirin-alone group.11
  • Blood glucose levels and hemoglobin A1C (HbA1C) were not systematically collected at baseline.36
  • The primary efficacy outcome was the composite of cardiovascular (CV) death, stroke, and MI and the principal safety outcome was modified International Society on Thrombosis and Hemostasis Major Bleeding. Results were consistent when stratified by patients with or without DM at baseline. See Table: Primary Efficacy and Safety Outcomes for the Comparison of XARELTO Plus Aspirin vs Aspirin Alone, Stratified by Baseline DM.9,12

Primary Efficacy and Safety Outcomes for the Comparison of XARELTO Plus Aspirin vs Aspirin Alone, Stratified by Baseline DM9,12
Baseline DM
XAR+Aspirin,
n/N (%)

Aspirin Alone,
n/N (%)

Hazard Ratio (95% CI)
Interaction P-Value
Composite Endpoint: CV death, stroke, or MI (primary efficacy endpoint)
Yes
179/3448 (5.2)
239/3474 (6.9)
0.74 (0.61-0.9)
0.77
No
200/5704 (3.5)
257/5652 (4.5)
0.77 (0.64-0.93)
Modified ISTH Major Bleeding
Yes
110/3448 (3.2)
65/3474 (1.9)
1.70 (1.25-2.31)
0.97
No
178/5704 (3.1)
105/5652 (1.9)
1.69 (1.33-2.15)
Abbreviations: CI, confidence interval; CV, cardiovascular; DM, diabetes mellitus; ISTH, International Society on Thrombosis and Hemostasis; MI, myocardial infarction; XAR, XARELTO.

Anand et al (2018)37 conducted a prespecified subanalysis of patients in the COMPASS study that had stable PAD. Of the total patients enrolled in the COMPASS study, 7470 (27%) had a history of PAD at baseline.

  • The primary efficacy and safety outcomes were the same as in the overall COMPASS study, which were previously described.
  • Several composite outcomes specific to PAD were also evaluated, including major adverse CV events (CV death, stroke, and MI) and MALEs (defined as the development of acute or chronic limb ischemia over the course of study follow-up, including any major amputations due to a vascular event that was not included in acute or chronic limb ischemia).
  • DM was reported at baseline in 44% (n=3287) of patients with PAD.
  • The effects of XARELTO plus aspirin vs aspirin alone on the combined outcome of major adverse CV events and MALEs including major amputation were consistent in patients with and without DM, as shown in Table: The Composite of Major Adverse CV Events and Major Adverse Limb Events Including Major Amputation, Stratified by DM.

The Composite of Major Adverse CV Events and Major Adverse Limb Events Including Major Amputation, Stratified by DM37
Baseline DM
XAR+Aspirin,
n/N (%)

Aspirin Alone,
n/N (%)

Hazard Ratio (95% CI)
Interaction P-Value
Yes
91/1100 (8)
128/1104 (12)
0.69 (0.53-0.91)
0.97
No
66/1392 (5)
97/1400 (7)
0.69 (0.5-0.94)
Abbreviations: CI, confidence interval; CV, cardiovascular; DM, diabetes mellitus; XAR, XARELTO.

Connolly et al (2018)38 conducted a prespecified subanalysis of patients in the COMPASS study that had stable CAD. Of the total patients enrolled in the COMPASS study, 24,824 (91%) had CAD.


Efficacy and Safety Outcomes for the Comparison of XARELTO Plus Aspirin vs Aspirin Alone, Stratified by Baseline DM38
Baseline DM
XAR+Aspirin,
n/N (%)

Aspirin Alone,
n/N (%)

Hazard Ratio (95% CI)
Interaction P-Value
Composite Endpoint: CV death, stroke, or MI (primary efficacy endpoint)
Yes
155/3043 (5.1)
212/3040 (7)
0.72 (0.58-0.88)
0.62
No
192/5270 (3.6)
248/5221 (4.8)
0.77 (0.64-0.93)
Modified ISTH Major Bleeding
Yes
99/3043 (3.3)
60/3040 (2)
1.65 (1.2-2.27)
0.95
No
164/5270 (3.1)
98/5221 (1.9)
1.67 (1.3-2.15)
Abbreviations: CI, confidence interval; CV, cardiovascular; DM, diabetes mellitus; ISTH, International Society on Thrombosis and Hemostasis; MI, myocardial infarction; XAR, XARELTO.

Bhatt et al (2020)39 conducted a prespecified subanalysis of patients in the COMPASS study to compare the effects of XARELTO (2.5 mg twice daily) plus aspirin (100 mg daily) vs placebo plus aspirin in patients with diabetes vs without diabetes.

  • The primary efficacy and safety outcomes were the same as in the overall COMPASS study, which were previously described.
  • Of the total patients enrolled in the COMPASS study, 10,341 patients had diabetes and 17,054 patients did not have diabetes.
  • Patients with diabetes were significantly younger (mean age: 67±8.2 years) and more likely female (24.4%) vs those without diabetes (mean age: 69±7.7 years; female: 20.5%).40
  • A consistent and similar relative risk reduction for benefit of XARELTO plus aspirin (N=9152) vs placebo plus aspirin (N=9126) was observed both in patients with diabetes (N=6922) and without diabetes (N=11,356) for the primary efficacy outcome (HR, 0.74; P=0.002 and HR, 0.77; P=0.005, respectively; Pinteraction=0.77) and all-cause mortality (HR, 0.81; P=0.05 and HR, 0.84; P=0.09, respectively; Pinteraction=0.82). See Table: Outcomes in Patients with and without Diabetes for XARELTO Plus Aspirin vs Placebo Plus Aspirin.
  • Although patients with diabetes had numerically larger absolute risk reductions compared to those without diabetes, similar benefit was observed among both subgroups (2.3% vs 1.4%, respectively, for the primary efficacy outcome at 3 years, Gail-Simon qualitative Pinteraction<0.0001; 1.9% vs 0.6%, respectively, for all-cause mortality, Pinteraction=0.02; 2.7% vs 1.7%, respectively, for major vascular events at 3 years, Pinteraction<0.0001).
  • Similar to the overall COMPASS study, the dual pathway regimen was associated with a significant increase in major bleeding in both subgroups, with a similar degree of risk increase (without diabetes: major bleeding increased at 3 years from 3.2% to 4.4%, HR, 1.69; 95% CI, 1.33-2.15; P<0.0001; with diabetes: major bleeding increased at 3 years from 3.4% to 4.5%, HR, 1.7; 95% CI, 1.25-2.31; P=0.0006, P interaction=0.97). See Table: Outcomes in Patients with and without Diabetes for XARELTO Plus Aspirin vs Placebo Plus Aspirin.
    • As bleeding hazards were similar among patients with and without diabetes, the prespecified net clinical benefit for XARELTO appeared favorable in those with diabetes (2.7% vs 1%, respectively: Gail-Simon qualitative Pinteraction=0.001).

Outcomes in Patients with and without Diabetes for XARELTO Plus Aspirin vs Placebo Plus Aspirin39
XAR+Aspirin
(n=9152)

Placebo+Aspirin
(n=9126)

XAR+Aspirin vs Placebo+Aspirin
P-Value for Interactiona
No. of First Events/Pts (%)
Kaplan-Meier Risk at 36 Months
No. of First Events/Pts (%)
Kaplan-Meier Risk at 36 Months
Hazard Ratio (95% CI)
P Value
Efficacy Outcomes
CV death, stroke, or MI
0.77
No diabetes at baseline
200/5704 (3.5)
5.8
257/5652 (4.5)
7.2
0.77 (0.64-0.93)
0.005
Diabetes at baseline
179/3448 (5.2)
8.4
239/3474 (6.9)
10.7
0.74 (0.61-0.90)
0.002
Death from any cause
0.82
No diabetes at baseline
166/5704 (2.9)
5.1
197/5652 (3.5)
5.7
0.84 (0.68-1.03)
0.09
Diabetes at baseline
147/3448 (4.3)
6.8
181/3474 (5.2)
8.6
0.81 (0.65-1.00)
0.05
Primary Safety Outcome
Major bleeding
0.97
No diabetes at baseline
178/5704 (3.1)
4.4
105/5652 (1.9)
3.2
1.69 (1.33-2.15)
<0.0001
Diabetes at baseline
110/3448 (3.2)
4.5
65/3474 (1.9)
3.4
1.7 (1.25-2.31)
0.0006
Net Clinical Benefit Outcome
CV death, stroke, MI, fatal bleeding, or symptomatic bleeding into critical organ
0.78
No diabetes at baseline
227/5704 (4.0)
6.6
276/5652 (4.9)
7.6
0.81 (0.68-0.97)
0.02
Diabetes at baseline
204/3448 (5.9)
9.1
258/3474 (7.4)
11.8
0.78 (0.65-0.94)
0.01
Abbreviations: CI, confidence interval; CV, cardiovascular; MI, myocardial infarction; no., number; pts, patients; XAR, XARELTO.
aTest of interaction of relative risk reduction (Cox regression).

VOYAGER PAD

VOYAGER PAD was a phase 3, multicenter, randomized, placebo-controlled, double-blind, international study designed to evaluate whether XARELTO 2.5 mg twice daily plus aspirin 100 mg once daily is more effective than aspirin 100 mg once daily alone for the risk reduction of major atherothrombotic vascular outcomes consisting of both CV and limb events in patients with symptomatic PAD undergoing lower extremity revascularization (LER).13

  • Patients with poorly controlled diabetes (at the discretion of the investigator) were excluded.14
  • Primary Efficacy Outcome: the composite of acute limb ischemia (ALI), major amputation of vascular etiology, MI, ischemic stroke, or CV death.13
  • Principal Safety Outcome: Major bleeding according to Thrombolysis in Myocardial Infarction (TIMI) classification.13
  • A total of 6564 patients were enrolled in the study and 40% (n=2629) of patients had DM. Of those 2629 patients, 40% (n=1313) had been in the XARELTO-plus-aspirin group and 40.1% (n=1316) had been in the aspirin-alone group.13
  • Results were stratified by age and are presented in Table: Primary Efficacy and Safety Outcomes for the VOYAGER PAD study, stratified by DM.

Primary Efficacy and Safety Outcomes for the VOYAGER PAD study, stratified by DM14
Baseline DM
XAR+Aspirin,
n/N (%)

Aspirin Alone,
n/N (%)

Hazard Ratio (95% CI)
Primary Efficacy Outcome: composite of ALI, major amputation of vascular etiology, MI, ischemic stroke, or CV death
Yes
248/1313 (18.89)
261/1316 (19.83)
0.94 (0.79-1.11)
No
260/1972 (13.18)
323/1961 (16.47)
0.79 (0.67-0.93)
Safety Outcome: Major bleeding according to TIMI classification
Yes
31/1298 (2.39)
13/1305 (1)
2.45 (1.28-4.69)
No
31/1958 (1.58)
31/1942 (1.6)
1.01 (0.61-1.66)
Abbreviations: ALI, acute limb ischemia; CI, confidence interval; CV, cardiovascular; DM, diabetes mellitus; MI, myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction; XAR, XARELTO.

Low Wang et al (2021)41 evaluated the risk profile of critical limb ischemia (CLI) patients with diabetes (n=716) compared to CLI patients without diabetes (n=817) from the VOYAGER PAD study.

  • Of the 6564 patients undergoing revascularization in the VOYAGER PAD study, 1533 presented with CLI.
  • The HR for the primary outcome at 3 years in CLI patients (all high risk) was 0.85, 95% CI, 0.69-1.05, with higher risk in the patients with diabetes (28.8%) vs patients without diabetes (20.7%).
  • The benefit and bleeding risk of XARELTO was consistent regardless of diabetes status in CLI patients.

Sharma et al (2023)15 conducted a post hoc analysis of the COMMANDER-HF study that compared the efficacy and safety of low-dose XARELTO in heart failure patients with sinus rhythm and coronary disease with diabetes vs without diabetes.

  • Of the 5022 patients randomized in the COMMANDER-HF study, 2052 and 2970 were with and without diabetes, respectively.
  • The median (interquartile range) age was 66 (59-74) years in both groups; 24.9% vs 21.5% of patients were female with vs without diabetes.
  • The primary efficacy outcome was a composite of death, nonfatal MI, or nonfatal stroke. The primary safety outcome was a composite of fatal bleeding and bleeding into a critical space with a potential for permanent disability.
  • The event rates per 100 PY for the primary efficacy outcome were 16.23 vs 11.81 for patients with vs without diabetes (adjusted HR, 1.34; 95% CI, 1.19-1.5).
  • The event rates per 100 PY for the primary safety outcome were 0.47 vs 0.38 for patients with vs without diabetes (adjusted HR, 1.06; 95% CI, 0.56-2.01).
  • The risk of CV death, nonfatal MI, or nonfatal stroke was similar in patients with diabetes (adjusted HR, 1; 95% CI, 0.85-1.18) and without diabetes (adjusted HR, 0.9; 95% CI, 0.77-1.04; Pinteraction=0.32).
  • No interaction was found between diabetes and XARELTO treatment with respect to fatal bleeding or bleeding into a critical space with a potential for permanent disability in patients with diabetes (adjusted HR, 0.81; 95% CI, 0.32-2.06) and without diabetes (adjusted HR, 0.76; 95% CI, 0.33-1.74; Pinteraction=0.92).

Arjunan et al (2026)17 conducted a real-world study at a tertiary care hospital in northern India from January 2022 to December 2023. The study enrolled 101 patients with PAD and T2DM who underwent lower limb revascularization by angioplasty, stenting, or bypass surgery.

  • Patients received XARELTO 2.5 mg twice daily in combination with aspirin 75 mg and were followed for 1 year after revascularization to assess MACE and MALE.
  • MACEs comprised CV death, nonfatal MI, and nonfatal stroke, whereas MALEs comprised repeat revascularization and major or minor limb amputation.
  • The median duration of DM was 11 years (interquartile range [IQR], 7-20).
  • Outcomes assessed 1 year after the revascularization procedure are summarized in Table: Effect of XARELTO in Combination with Aspirin on Clinical Outcomes.

Effect of XARELTO in Combination with Aspirin on Clinical Outcomes17
Outcome
n (%)
MALE
62 (61.4)
Major amputation
17 (16.8)
Minor amputation
45 (44.6)
MACE
34 (33.7)
CAD
10
CVA
1
Wound healed
16 (15.8)
Abbreviations: CAD, coronary artery disease; CVA, cerebrovascular accident; MACE, major adverse cardiovascular event; MALE, major adverse limb event.
  • During the 1-year follow-up, 10 patients had a nonfatal MI, 1 had a nonfatal ischemic stroke, and 23 (22.8%) died.
    • Of the 23 deaths, 15 (65.2%) were attributed to CAD, 2 (8.7%) to chronic kidney disease (CKD), 2 (8.7%) to infections, 2 (8.7%) to cerebrovascular accidents (CVAs), 1 (4.35%) to hyperosmolar nonketotic coma (HONK), and 1 (4.35%) to an unknown cause.
  • Grade I hemorrhage was reported in 3 patients, with a hemoglobin reduction of <5 g/dL in each case.
    • A nonfatal hemorrhagic stroke occurred in 1 patient 4 months after initiation of XARELTO.

Salle et al (2026)18 conducted a prospective study using data from the XATOA (Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis) registry to assess the clinical characteristics and outcomes of patients with DM and CVD initiating DPI with XARELTO 2.5 mg twice daily plus aspirin in clinical practice. The registry enrolled patients with CAD and/or PAD.

  • Among 5532 patients enrolled in XATOA, 2130 (38.5%) had DM, predominantly T2DM (96.1%).
  • Patients with DM had a 59% higher risk of MAVE, including MACE and MALE, compared with patients without DM (P<0.001).
  • Among patients with DM, event rates were 2.1, 10.1, and 14.2 per 100 patient-years in those with CAD, CAD+PAD, and PAD alone, respectively.
  • The major bleeding rate was 4.3 per 100 patient-years and was similar across diabetes status and vascular territories.

Atrial Fibrillation

Chen et al (2026)19 conducted a retrospective cohort study using data from the clinical database of Tri-Service General Hospital in northern Taiwan to compare the effectiveness and safety of XARELTO, apixaban, dabigatran, and edoxaban in patients with both DM and AF.

  • Patients with AF and DM who initiated NOAC therapy and received treatment for >3 months between December 2012 and June 2022 were eligible for inclusion.
  • Study outcomes included MACEs, major bleeding events, and all-cause mortality.
  • Of the 7229 patients treated with apixaban, dabigatran, edoxaban, or XARELTO for >3 months, 1382 had a diagnosis of DM and AF before NOAC exposure.
  • The final cohort included 1320 patients: 536 (40.6%) received XARELTO, 396 (30%) received apixaban, 175 (13.3%) received dabigatran, and 213 (16.1%) received edoxaban.
  • Following propensity score matching, 700 patients, with 175 patients in each treatment group, were included in the final analysis.
  • The average daily dose of XARELTO was 12.93±2.59 mg, compared with the recommended standard dose of 20 mg/day. The study outcomes are summarized in Table: Complications, Mortality, and Associated HRs in Patients with AF and Diabetes Receiving XARELTO.

Complications, Mortality, and Associated HRs in Patients with AF and Diabetes Receiving XARELTO19
Complication
XARELTO
(n=175)

HR (95% CI)
P-Value
Total MACE
12
0.65 (0.32-1.35)
0.251
   Acute myocardial
   infarction

3
0.68 (0.16-2.83)
0.591
   Ischemic stroke
6
0.52 (0.2-1.35)
0.177
   Cardiovascular death
3
2.58 (0.26-25.96)
0.421
Major bleeding events
15
1.61 (0.72-3.6)
0.242
   Intracranial
   hemorrhage

4
4.42 (0.49-39.55)
0.184
   Gastrointestinal
   bleeding

11
1.22 (0.5-2.94)
0.664
All-cause mortality
14
1.06 (0.49-2.28)
0.878
Note: HRs are based on comparisons with apixaban.
Abbreviations
: AF, atrial fibrillation; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular event.

Venous Thromboembolism

Ruigómez et al (2024)20 conducted a study using healthcare databases from 4 European countries, Germany, the Netherlands, Sweden, and the UK, to evaluate the safety of XARELTO compared with VKAs in patients receiving treatment for and secondary prevention of VTE. The study also evaluated mortality risk and bleeding outcomes among XARELTO users according to older age, renal function, and diabetes.

  • Patients aged ≥2 years who were first-time users of XARELTO or VKAs were enrolled from December 9, 2011, in Germany, the Netherlands, and Sweden, and from January 1, 2012, in the UK. Enrollment continued through December 31, 2016, in Germany and December 31, 2017, in the UK, the Netherlands, and Sweden.
    • The observation period ended 1 year after the end of the enrollment period.
  • Data were obtained from the IQVIA Medical Research Data (IMRD) incorporating The Health Improvement Network (THIN), a Cegedim database; the German Pharmacoepidemiological Research Database; the PHARMO Database Network (Netherlands); and Swedish nationwide health registries.
  • Safety outcomes included bleeding events leading to hospitalization, categorized as intracranial hemorrhage, gastrointestinal bleeding, urogenital bleeding, and bleeding at other sites. All-cause mortality was also evaluated among XARELTO users. See Table: IRs of Bleeding Leading to Hospitalization and Mortality in First-Time XARELTO Users with Type 1 or Type 2 Diabetes Mellitus.
  • The analyses included 44,737 patients treated with XARELTO and 45,842 patients treated with VKAs.

IRs of Bleeding Leading to Hospitalization and Mortality in First-Time XARELTO Users with Type 1 or Type 2 Diabetes Mellitus20
Outcome
Country
Events, n
Person-years
IR (95% CI)
Intracranial bleeding
UK
(n=5680)

0
493
0
Netherlands
(n=586)

0
51
N/A
Germany
(n=25,914)

19
5776.4
0.33 (0.2-0.51)
Sweden
(n=12,557)

7
798
0.88 (0.42-1.84)
Gastrointestinal bleeding
UK
(n=5680)

4
490
0.81 (0.22-2.09)
Netherlands
(n=586)

0
49
N/A
Germany
(n=25,914)

96
5725.6
1.68 (1.36-2.05)
Sweden
(n=12,557)

14
791
1.77 (1.05-2.99)
Urogenital bleeding
UK
(n=5680)

2
488.2
0.41 (0.05-1.48)
Netherlands
(n=586)

0
49
N/A
Germany
(n=25,914)

33
5752.9
0.57 (0.39-0.81)
Sweden
(n=12,557)

9
797
1.13 (0.59-2.17)
Other bleeding
UK
(n=5680)

1
492
0.2 (0.01-1.13)
Netherlands
(n=586)

0
51
N/A
Germany
(n=25,914)

32
5754.4
0.56 (0.38-0.79)
Sweden
(n=12,557)

4
797
0.5 (0.19-1.34)
Mortality
UK
(n=5680)

30
493
6.08 (4.11-8.69)
Netherlands
(n=586)

1
49
2 (0-8.1)
Germany
(n=25,914)

296
5782.9
5.12 (4.55-5.74)
Sweden
(n=12,557)

41
799
5.13 (3.78-6.97)
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; IR, incidence rate; N/A, not available; UK, United Kingdom.

LITERATURE SEARCH

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, Derwent® (and/or other resources, including internal/external databases) was conducted on 15 October 2026.

 

References

1 Bansilal S, Bloomgarden Z, Halperin JL, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J. 2015;170(4):675-682.e8.  
2 Patel MR, Tamayo S, Yuan Z, et al. Major bleeding among rivaroxaban users with nonvalvular atrial fibrillation and diabetes. Poster presented at: ACC Conference Meeting; April 2-4, 2016; Chicago, IL.  
3 Coleman CI, Bunz TJ, Eriksson D, et al. Effectiveness and safety of rivaroxaban vs warfarin in people with non‐valvular atrial fibrillation and diabetes: an administrative claims database analysis. Diabet Med. 2018;35(8):1105-1110.  
4 Lip GYH, Keshishian AV, Kang AL, et al. Effectiveness and safety of oral anticoagulants in patients with nonvalvular atrial fibrillation and diabetes mellitus. Mayo Clin Proc. 2020;95(5):929-943.  
5 Coleman CI, Costa OS, Brescia CW, et al. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin. Cardiovasc Diabetol. 2021;20(1):52.  
6 Costa OS, O’Donnell B, Vardar B, et al. Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis. Curr Med Res Opin. 2021;37(9):1493-1500.  
7 Chowdhury KR, Michaud J, Yu OHY, et al. Effectiveness and safety of apixaban versus rivaroxaban in patients with atrial fibrillation and type 2 diabetes mellitus. Thromb Haemost. 2022;122(10):1794-1803.  
8 Coleman CI, Costa OS, Brescia CW, et al. A RIVA-DM subanalysis investigating patients with nonvalvular atrial fibrillation and type 2 diabetes aged under versus over 80 years. Clin Appl Thromb Hemost. 2022;28:10760296221133083.  
9 Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-1330.  
10 Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People using Anticoagulation Strategies (COMPASS) trial. Can J Cardiol. 2017;33(8):1027-1035.  
11 Data on File. COMPASS Clinical Study Report. Johnson & Johnson Pharmaceutical Research and Development, LLC; 2017.  
12 Eikelboom JW, Connolly SJ, Bosch J, et al. Supplement to: Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-1330.  
13 Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994-2004.  
14 Bonaca MP, Bauersachs RM, Anand SS, et al. Supplement to: Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994-2004.  
15 Sharma A, Caldeira D, Razaghizad A, et al. Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF. BMJ Open. 2023;13(8):e068865.  
16 Data on File. Meta analysis of the EINSTEIN-DVT and EINSTEIN-PE treatment studies: clinical study report. Johnson & Johnson Pharmaceutical Research and Development, LLC; 2012.  
17 Arjunan D, Ghosh J, Rastogi A, et al. MACE and MALE outcome with rivaroxaban following endovascular peripheral arterial intervention in diabetes: a real-world study. Int J Diabetes Dev Ctries. 2026;46(2):436-441.  
18 Salle L, Aboyans V, Vogtländer K, et al. Characteristics and outcomes of patients with diabetes mellitus selected for dual pathway inhibition in clinical practice: the XATOA registry. Vasc Med. 2026;31(4):493-504.  
19 Chen HH, Lin C, Lin CS, et al. Impact of non-vitamin K antagonist oral anticoagulants on cardiovascular outcomes in diabetes patients with atrial fibrillation: a single-center experience. Acta Cardiol Sin. 2026;42(5):733-744.  
20 Ruigómez A, Schink T, Voss A, et al. Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. PLoS One. 2024;19(3):e0298596.  
21 Burnhope E, Boos CJ. Novel anticoagulants for stroke prevention in atrial fibrillation among diabetics. Br J Diabetes Vasc Dis. 2013;13(1):51-55.  
22 Iba T, Aihara K, Yamada A, et al. Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus. Thromb Res. 2014;133(2):276-280.  
23 Peacock WF, Tamayo S, Sicignano N, et al. Comparison of the incidence of major bleeding with rivaroxaban use among nonvalvular atrial fibrillation patients with versus without diabetes mellitus. Am J Cardiol. 2017;119(5):753-759.  
24 Ugowe FE, Hellkamp AS, Wang A, et al. Pharmacotherapy for diabetes and stroke risk: results from ROCKET AF. Heart Rhythm O2. 2021;2(3):215-222.  
25 Weir MR, Chen YW, He J, et al. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes. J Diabetes Complications. 2021;35(11):108029.  
26 Weir MR, Chen YW, He J, et al. Healthcare resource utilization and costs of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes. Diabetes Ther. 2021;12(12):3167-3186.  
27 Vaitsiakhovich T, Coleman CI, Kleinjung F, et al. Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study. Curr Méd Res Opin. 2022;38(6):937-945.  
28 González Pérez A, Balabanova Y, Sáez ME, et al. Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: a population-based study from the United Kingdom. Int J Cardiol. 2022;352:165-171.  
29 Abdullaev S, Igamberdieva R. Direct oral anticoagulants in patients with atrial fibrillation and obesity, type two diabetes, CKD [abstract]. Nephrol Dial Transplant. 37(Suppl. 3):gfac076.031.  
30 Lu M, Li J, Ni H, et al. Clopidogrel combined with rivaroxaban in peripheral artery disease after revascularization. Front Pharmacol. 2025;15:1485380.  
31 Rizzi A, Petrucci G, Sacco M, et al. Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study. Diabetes Res Clin Pract. 2025;224:112244.  
32 Li G, Chen C, Wang H, et al. Multifactorial risk assessment and anticoagulation strategy optimization for deep vein thrombosis after major joint surgery: a retrospective study. J Vis Exp. 2026;(232).  
33 Li Y, Zhou T, Liu Y, et al. Low-dose rivaroxaban vs. aspirin in addition to clopidogrel after percutaneous coronary intervention in coronary atherosclerotic heart disease patients with gastrointestinal disease. Cardiovasc Drugs Ther. 2026;40(1):201-211.  
34 Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.  
35 Chowdhury KR, Michaud J, Yu OHY, et al. Supplement to: Effectiveness and safety of apixaban versus rivaroxaban in patients with atrial fibrillation and type 2 diabetes mellitus. Thromb Haemost. 2022;122(10):1794-1803.  
36 Data on File. Internal Communication. Janssen Research & Development, LLC; 2018.  
37 Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219-229.  
38 Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-218.  
39 Bhatt DL, Eikelboom JW, Connolly SJ, et al. Role of combination antiplatelet and anticoagulation therapy in diabetes and cardiovascular disease: insights from the COMPASS trial. Circulation. 2020;141(23):1841-1854.  
40 Bhatt DL, Eikelboom JW, Connolly SJ, et al. Supplement to: Role of combination antiplatelet and anticoagulation therapy in diabetes and cardiovascular disease: insights from the COMPASS trial. Circulation. 2020;141(23):1841-1854.  
41 Wang CCL, Nehler MR, Haskell L, et al. Risk profile of comorbid diabetes and benefit of rivaroxaban in patients with critical limb ischemia: insights from VOYAGER PAD [abstract]. Diabetes. 2021;70(Supplement_1):8-LB.  

Would you like to clear and leave your conversation? Message history will be lost.